1 Guidance
1.1 Sofosbuvir is recommended as an option for treating chronic hepatitis C in adults, as specified in table 1.
Table 1 Sofosbuvir for treating adults with chronic hepatitis C
Sofosbuvir in combination with peginterferon alfa and ribavirin |
Sofosbuvir in combination with ribavirin |
|||
Genotype |
Treatment history |
Recommendation |
Treatment history |
Recommendation |
Adults with genotype 1 HCV |
All |
Recommended |
All |
Not recommended |
Adults with genotype 2 HCV |
All |
Not licensed for this population |
Treatment-naive |
Only recommended for people who are intolerant to or ineligible for interferon |
Treatment-experienced |
Recommended |
|||
Adults with genotype 3 HCV |
Treatment-naive |
Only recommended for people with cirrhosis |
Treatment-naive |
Only recommended for people with cirrhosis who are intolerant to or ineligible for interferon |
Treatment-experienced |
Recommended |
Treatment-experienced |
Only recommended for people with cirrhosis who are intolerant to or ineligible for interferon |
|
Adults with genotype 4, 5 or 6 HCV |
All |
Only recommended for people with cirrhosis |
All |
Not recommended |
HCV – hepatitis C virus Treatment‑naive – the person has not had treatment for chronic hepatitis C Treatment‑experienced – the person's hepatitis C has not adequately responded to interferon‑based treatment |
1.2 People currently receiving treatment initiated within the NHS with sofosbuvir that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.